-
公开(公告)号：US20230338376A1
公开(公告)日：2023-10-26
申请号：US18152993
申请日：2023-01-11
Applicant: Deciphera Pharmaceuticals, LLC
Inventor： Daniel L. Flynn , Yu Mi Ahn , Timothy Caldwell , Lakshminarayana Vogeti
IPC: A61K31/506 , A61P35/00 , A61K31/4184 , A61K31/437 , A61K31/4439 , A61K31/4523 , A61K31/475 , A61K31/496 , A61K31/513 , A61K31/519 , A61K31/5377 , A61K31/706 , A61K31/7068 , A61K45/06 , C07D239/48 , C07D401/12 , C07D401/14 , C07D403/12
CPC classification number: A61K31/506 , A61P35/00 , A61K31/4184 , A61K31/437 , A61K31/4439 , A61K31/4523 , A61K31/475 , A61K31/496 , A61K31/513 , A61K31/519 , A61K31/5377 , A61K31/706 , A61K31/7068 , A61K45/06 , C07D239/48 , C07D401/12 , C07D401/14 , C07D403/12
Abstract: Described herein are compounds that are inhibitors of autophagy and their use in the treatment of disorders such as cancers.
-
公开(公告)号：US20230047915A1
公开(公告)日：2023-02-16
申请号：US17832224
申请日：2022-06-03
Applicant: Deciphera Pharmaceuticals, LLC
Inventor： Daniel L. Flynn , Yu Mi Ahn , Timothy Caldwell , Lakshminarayana Vogeti
IPC: C07D403/14 , A61P35/04 , C07D413/14 , C07D401/14 , C07D405/14
Abstract: Described herein are compounds that are inhibitors of autophagy and their use in the treatment of disorders such as cancers.
-
公开(公告)号：US11530206B2
公开(公告)日：2022-12-20
申请号：US16870384
申请日：2020-05-08
Applicant: Deciphera Pharmaceuticals, LLC
Inventor： Daniel L. Flynn , Yu Mi Ahn , Timothy Caldwell , Lakshminarayana Vogeti
IPC: C07D401/12 , C07D401/14 , C07D403/12 , C07D403/14 , C07D413/14 , C07D417/04 , C07D487/04 , C07D487/08 , A61K31/506 , A61K31/444 , A61P35/00 , A61K31/519 , A61K45/06
Abstract: Described herein are compounds that are inhibitors of autophagy and their use in the treatment of disorders such as cancers.
-
4.发明授权Imidazolidinones and analogs exhibiting anti-cancer and anti-proliferative activities 有权具有抗癌和抗增殖活性的咪唑啉酮和类似物公开(公告)号：US09133183B2
公开(公告)日：2015-09-15
申请号：US14214134
申请日：2014-03-14
Applicant: Deciphera Pharmaceuticals, LLC
Inventor： Daniel L. Flynn , Michael D. Kaufman , Thiwanka Samarakoon , Timothy Malcolm Caldwell , Lakshminarayana Vogeti , YuMi Ahn , William C. Patt , Karen M. Yates
IPC: A61K31/497 , C07D417/14 , C07D401/14 , C07D405/14 , C07D413/14
CPC classification number: C07D417/14 , C07B59/002 , C07B2200/05 , C07D401/14 , C07D405/14 , C07D413/14
Abstract: Described are compounds of Formula I which find utility in the treatment of cancer, autoimmune diseases and metabolic bone disorders through inhibition of c-FMS (CSF-1R), c-KIT, and/or PDGFR kinases. These compounds also find utility in the treatment of other mammalian diseases mediated by c-FMS, c-KIT, or PDGFR kinases.
Abstract translation: 描述了通过抑制c-FMS（CSF-1R），c-KIT和/或PDGFR激酶在治疗癌症，自身免疫疾病和代谢性骨骼疾病中有用的式I化合物。 这些化合物也可用于治疗由c-FMS，c-KIT或PDGFR激酶介导的其它哺乳动物疾病。
-
5.发明授权N-acyl-N′-(pyridin-2-yl) ureas and analogs exhibiting anti-cancer and anti-proliferative activities 有权N-酰基-N' - （吡啶-2-基）脲和表现出抗癌和抗增殖活性的类似物公开(公告)号：US09309224B2
公开(公告)日：2016-04-12
申请号：US14214179
申请日：2014-03-14
Applicant: Deciphera Pharmaceuticals, LLC
Inventor： Daniel L. Flynn , Timothy Malcolm Caldwell , Thiwanka Samarakoon , Lakshminarayana Vogeti , Michael D. Kaufman , William C. Patt , YuMi Ahn
IPC: C07D213/65 , C07D401/14 , C07D401/12 , C07D405/14 , C07D493/08
CPC classification number: C07D401/12 , C07D401/14 , C07D405/14 , C07D493/08
Abstract: Described are compounds of Formula 1 which find utility in the treatment of cancer, autoimmune diseases and metabolic bone disorders through inhibition of c-FMS (CSF-1R), c-KIT, and/or PDGFR kinases. These compounds also find utility in the treatment of other mammalian diseases mediated by c-FMS, c-KIT, or PDGFR kinases.
Abstract translation: 描述了通过抑制c-FMS（CSF-1R），c-KIT和/或PDGFR激酶在治疗癌症，自身免疫性疾病和代谢性骨骼疾病中有效的式1化合物。 这些化合物也可用于治疗由c-FMS，c-KIT或PDGFR激酶介导的其它哺乳动物疾病。
-
Patent Agency Ranking
6.发明申请N-Acyl-N'-(pyridin-2-yl) Ureas and Analogs Exhibiting Anti-Cancer and Anti-Proliferative Activities 有权N-酰基-N' - （吡啶-2-基）脲和类似物展示抗癌和抗增殖活性公开(公告)号：US20140275016A1
公开(公告)日：2014-09-18
申请号：US14214179
申请日：2014-03-14
Applicant: Deciphera Pharmaceuticals, LLC
Inventor： Daniel L. Flynn , Timothy Malcolm Caldwell , Thiwanka Samarakoon , Lakshminarayana Vogeti , Michael D. Kaufman , William C. Patt , YuMi Ahn
IPC: C07D401/12 , C07D401/14 , C07D493/08 , C07D405/14
CPC classification number: C07D401/12 , C07D401/14 , C07D405/14 , C07D493/08
Abstract: Described are compounds of Formula 1 which find utility in the treatment of cancer, autoimmune diseases and metabolic bone disorders through inhibition of c-FMS (CSF-1R), c-KIT, and/or PDGFR kinases. These compounds also find utility in the treatment of other mammalian diseases mediated by c-FMS, c-KIT, or PDGFR kinases.
Abstract translation: 描述了通过抑制c-FMS（CSF-1R），c-KIT和/或PDGFR激酶在治疗癌症，自身免疫性疾病和代谢性骨骼疾病中有用的式1化合物。 这些化合物也可用于治疗由c-FMS，c-KIT或PDGFR激酶介导的其它哺乳动物疾病。
-
公开(公告)号：US20240150368A1
公开(公告)日：2024-05-09
申请号：US18456831
申请日：2023-08-28
Applicant: Deciphera Pharmaceuticals, LLC
Inventor： Justin T. Proto , Andrew Michael Harned , Kristen Stoltz , Timothy Caldwell , Lakshminarayana Vogeti , Yu Mi Ahn , Bertrand Le Bourdonnec , Daniel L. Flynn
IPC: C07D487/10 , A61K45/06 , C07D209/34 , C07D401/14 , C07D403/12 , C07D405/14 , C07D413/12 , C07D487/04 , C07D487/08 , C07D491/107
CPC classification number: C07D487/10 , A61K45/06 , C07D209/34 , C07D401/14 , C07D403/12 , C07D405/14 , C07D413/12 , C07D487/04 , C07D487/08 , C07D491/107
Abstract: Described herein are compounds that are inhibitors of autophagy and their use in the treatment of disorders such as cancers.
-
公开(公告)号：US11518758B2
公开(公告)日：2022-12-06
申请号：US16870418
申请日：2020-05-08
Applicant: Deciphera Pharmaceuticals, LLC
Inventor： Daniel L. Flynn , Yu Mi Ahn , Timothy Caldwell , Lakshminarayana Vogeti
IPC: C07D403/14 , C07D401/14 , C07D405/14 , C07D413/14 , A61P35/04 , A61K31/519 , A61K45/06
Abstract: Described herein are compounds that are inhibitors of autophagy and their use in the treatment of disorders such as cancers.
-
9.发明授权2-aminopyrimidin-6-ones and analogs exhibiting anti-cancer and anti-proliferative activities 有权2-氨基嘧啶-6-酮和具有抗癌和抗增殖活性的类似物公开(公告)号：US09181223B2
公开(公告)日：2015-11-10
申请号：US14214171
申请日：2014-03-14
Applicant: Deciphera Pharmaceuticals, LLC
Inventor： Michael D. Kaufman , Daniel L. Flynn , YuMi Ahn , Lakshminarayana Vogeti , Timothy Malcolm Caldwell
IPC: A61K31/506 , C07D401/14 , C07D405/14
CPC classification number: C07D401/14 , A61K31/506 , C07D405/14
Abstract: Described are compounds of Formula I which find utility in the treatment of cancer, autoimmune diseases and metabolic bone disorders through inhibition of c-FMS (CSF-1R), c-KIT, and/or PDGFR kinases. These compounds also find utility in the treatment of other mammalian diseases mediated by c-FMS, c-KIT, or PDGFR kinases.
Abstract translation: 描述了通过抑制c-FMS（CSF-1R），c-KIT和/或PDGFR激酶在治疗癌症，自身免疫疾病和代谢性骨骼疾病中有用的式I化合物。 这些化合物也可用于治疗由c-FMS，c-KIT或PDGFR激酶介导的其它哺乳动物疾病。
-
公开(公告)号：US20150119392A1
公开(公告)日：2015-04-30
申请号：US14383799
申请日：2013-03-05
Applicant: Deciphera Pharmaceuticals, LLC , Eli Lilly and Company
Inventor： Daniel L. Flynn , Michael D. Kaufman , Lakshminarayana Vogeti , Scott Wise , Wei-Ping Lu , Bryan Smith , James R. Henry , Philip A. Hipskind , Sheng-Bin Peng
IPC: C07D471/04
CPC classification number: C07D471/04 , C07D471/12
Abstract: This invention provides compounds of Formula I: (Formula I should be inserted here) or a pharmaceutically acceptable salt thereof; pharmaceutical compositions comprising a compound of Formula I; and use of a compound of Formula I for treating specified cancers.
Abstract translation: 本发明提供了式I化合物：（式I应该在此插入）或其药学上可接受的盐; 包含式I化合物的药物组合物; 以及式I化合物用于治疗特定癌症的用途。
-
-
-
-
-
-
-
-
-
Search Results
24
records
(took 0.034 seconds)
